Hepatic steatosis:A benign disease or a silent killer

作     者：Abdel-Rahman El-Zayadi 

作者机构：Tropical Medicine DepartmentAin Shams University and Cairo Liver CenterGiza12311Egypt 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2008年第14卷第26期

页      面：4120-4126页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：丙型肝炎 胰岛素抵抗 肝纤维化 脂肪变性 

摘      要：Steatosis is a common feature of many liver diseases,namely non-alcoholic steatohepatitis(NASH) and hepatitis C virus(HCV) infection,but the pathogenic mechanisms *** resistance(IR),a key feature of metabolic syndrome,is crucial for NASH development,associated with many underlying genetically determined or acquired mitochondrial and metabolic defects and culminates to inflammation and progression to *** may have potential implications for new drug *** HCV-related disease,steatosis impacts both fibrosis progression and response to *** in HCV-related disease relates to both viral factors(HCV genotype 3),and host factors(alcohol consumption,overweight,hyperlipidemia,diabetes).Among others,IR is a recognized *** steatosis is reported to be associated with disturbance in the signaling cascade of interferon and downregulation of its ***,hepatic steatosis should not be considered a benign feature,but rather a silent killer.